Testing a new cancer medication combined with standard chemotherapy

Plain-English translation of NCT06890884 on ClinicalTrials.gov ↗ · Source last updated August 2026 · Translation generated August 2026 · How we translate trials

Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.

What is this trial?

This study is testing whether works better than another similar medication when combined with a standard chemotherapy regimen for people with a specific type of fast-growing blood cancer called germinal center B-cell diffuse large B-cell lymphoma. Researchers want to know if more people who receive this medication and chemotherapy combination will see their cancer go away compared to those receiving the other medication and the same chemotherapy. You would be randomly assigned to receive one of the two treatment combinations.

This type of blood cancer is aggressive and fast-growing, and doctors are looking for better ways to treat it. This medication is designed to target cancer cells in a new way, and researchers want to see if adding it to standard chemotherapy helps more patients achieve remission.

Do you qualify?

You likely qualify if…

you have been diagnosed with germinal center B-cell diffuse large B-cell lymphoma that has been confirmed by a biopsy
you have never received any treatment for this cancer before
your cancer shows activity on a PET scan (rated 4-5 on the Lugano scale)
your HIV is well-controlled on medication (if you are HIV-positive), or your hepatitis B or C is undetectable or being treated appropriately
you have stage II or higher cancer (not stage I)

You likely don't qualify if…

you have active or recent heart disease, including a heart attack or stroke in the past 6 months
you have ongoing nerve damage or a demyelinating form of Charcot-Marie-Tooth disease
you are currently taking corticosteroid therapy (ongoing steroid medications)
you have an active infection or active autoimmune disease that requires treatment
you have a history of organ or stem cell transplant

What participation looks like

You would receive intravenous (IV) infusions every 3 weeks for up to 6 cycles, with some participants receiving 2 additional cycles depending on their risk level. Each cycle includes the new medication combined with standard chemotherapy drugs, and you would also take oral steroid tablets for 5 days of each cycle. The entire treatment would take approximately 4 months, and you would be monitored regularly for how well the treatment is working and for any side effects.

AI-generated summary from trial data · Aug 25, 2026 · Not medical advice

Testing a new cancer medication combined with standard chemotherapy

What is this trial?

Do you qualify?

What participation looks like

Trial locations